ADVANZ PHARMA Corp. Limited in its U$76 million acquisition of Correvio Pharma Corp.

On May 27, 2020, ADVANZ PHARMA Corp. Limited ("ADVANZ") announced the completion of its plan of arrangement (the "Arrangement") with specialty pharmaceutical company Correvio Pharma Corp. ("Correvio"). Pursuant to the Arrangement, ADVANZ, through a wholly-owned subsidiary, acquired all of the issued and outstanding common shares of Correvio for US$0.42 in cash consideration per share, valuing Correvio’s equity at approximately US$28 million on a fully diluted basis. The acquisition had a total purchase price of approximately US$76 million, which included the repayment of certain Correvio indebtedness.